Reviewing the 13 IPIX PRs relating to COVID-19, it
Post# of 72445
(Total Views: 729)
Posted On: 04/30/2020 3:09:32 AM
Reviewing the 13 IPIX PRs relating to COVID-19, it appears that IPIX is concurrently going down 2 paths for COVID-19. Either/both of these paths could lead to Brilacidin being fast tracked through a Phase 3 trial as a treatment and potential adjuvant to a vaccine for COVID-19. We could hear news on either path very soon.
Path 1 is the first MTA with the RBL and most of the 13 PRs discuss the RBL testing in detail. Next step is human lung cell testing that will start next week.
Path 2 is a 2nd MTA with “A major University” initially PRed on 3/6/20 with the following:
Today, the Company announces that a second MTA has been signed to ship Brilacidin to a major U.S. university for analysis. One of world’s leading coronavirus experts is overseeing the research. Innovation management is awaiting approval from the university to disclose additional details on the agreement and hopes to further inform shareholders next week regarding this development.
And then on 3/17/20:
WAKEFIELD, MA – March 17, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the Material Transfer Agreement (MTA) signed with a leading public health-focused U.S. university and top coronavirus expert. Under the terms of the confidential agreement, virologists plan to evaluate the potential antiviral properties of Brilacidin, the Company’s lead defensin-mimetic drug candidate, toward developing Brilacidin as a potential novel coronavirus (COVID-19) vaccine.
And then on 4/6/20 – (Note the key word “supported”)
WAKEFIELD, MA – April 6, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic.
Their interest in Brilacidin as a treatment for COVID-19 and associated complications is based on the drug’s promising antiviral activity against SARS-CoV-2, as supported in preliminary testing conducted in a monkey epithelial cell line, and its established anti-inflammatory and antimicrobial properties—a potential 3-in-1 treatment combination. In advance of potential clinical testing, the Company is investigating procurement of appropriate drug supply (i.e., manufacture of intravenous drug product), and preparing for engagement with regulatory authorities.
And then on 4/20/20:
The Company also continues to engage in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials.
Additional pre-clinical and clinical data support Brilacidin’s therapeutic potential to inhibit the production of IL-6, IL-1b, TNF-a and other pro-inflammatory cytokines and chemokines (e.g., MCP-1), identified as central drivers in the worsening prognoses of COVID-19 patients. Brilacidin’s antimicrobial properties might also help in fighting secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. Collectively, these data support Brilacidin as a promising and unique (a 3 in 1 combination: antiviral, immune/anti-inflammatory, and antimicrobial) anti-COVID-19 therapeutic candidate.
Path 1 is the first MTA with the RBL and most of the 13 PRs discuss the RBL testing in detail. Next step is human lung cell testing that will start next week.
Path 2 is a 2nd MTA with “A major University” initially PRed on 3/6/20 with the following:
Today, the Company announces that a second MTA has been signed to ship Brilacidin to a major U.S. university for analysis. One of world’s leading coronavirus experts is overseeing the research. Innovation management is awaiting approval from the university to disclose additional details on the agreement and hopes to further inform shareholders next week regarding this development.
And then on 3/17/20:
WAKEFIELD, MA – March 17, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the Material Transfer Agreement (MTA) signed with a leading public health-focused U.S. university and top coronavirus expert. Under the terms of the confidential agreement, virologists plan to evaluate the potential antiviral properties of Brilacidin, the Company’s lead defensin-mimetic drug candidate, toward developing Brilacidin as a potential novel coronavirus (COVID-19) vaccine.
And then on 4/6/20 – (Note the key word “supported”)
WAKEFIELD, MA – April 6, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic.
Their interest in Brilacidin as a treatment for COVID-19 and associated complications is based on the drug’s promising antiviral activity against SARS-CoV-2, as supported in preliminary testing conducted in a monkey epithelial cell line, and its established anti-inflammatory and antimicrobial properties—a potential 3-in-1 treatment combination. In advance of potential clinical testing, the Company is investigating procurement of appropriate drug supply (i.e., manufacture of intravenous drug product), and preparing for engagement with regulatory authorities.
And then on 4/20/20:
The Company also continues to engage in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials.
Additional pre-clinical and clinical data support Brilacidin’s therapeutic potential to inhibit the production of IL-6, IL-1b, TNF-a and other pro-inflammatory cytokines and chemokines (e.g., MCP-1), identified as central drivers in the worsening prognoses of COVID-19 patients. Brilacidin’s antimicrobial properties might also help in fighting secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. Collectively, these data support Brilacidin as a promising and unique (a 3 in 1 combination: antiviral, immune/anti-inflammatory, and antimicrobial) anti-COVID-19 therapeutic candidate.
(17)
(0)